Devonian Health Group Inc. (V:GSD)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Mar 28, 2024 08:45 am ET

Devonian Health Group Reports Second Quarter 2024 Financial Results and Business Update

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its second quarter ended on January 31, 2024.

Mar 14, 2024 08:45 am ET

Devonian Announces Closing of a Private Placement of Units

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of $223,800.00 (the “Offering”), effective March 13, 2024. The Offering consisted of the issuance of 1,492,000 units of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit consists of on

Feb 29, 2024 09:01 am ET

Devonian Names Kathryn J. Gregory to the Board of Directors and Grants Stock Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the board of directors of the Corporation (the “Board”) has appointed pharmaceutical industry veteran Ms. Kathryn J. Gregory to the Board, effective February 28, 2024.

Feb 27, 2024 08:45 am ET

Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that its wholly-owned subsidiary, Altius Healthcare Inc. (“Altius”), has launched the first authorized generic of dexlansoprazole (Dexilant®) in Canada to treat symptoms of gastroesophageal reflux disease (GERD).

Feb 26, 2024 04:30 pm ET

Devonian Announces a $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that it has entered into a twelve (12) month term loan in a principal of $2,160,000 (the “Loan”) from Fiera Private Debt Inc. (“Fiera”), following the repayment of its $3,500,000 long term loan, which matured January 17, 2024. The Loan will be used for general corporate purposes.

Feb 21, 2024 08:45 am ET

Devonian Announces the Results of its Annual General and Special Shareholders' Meeting, the Approval of Amendments to its Stock Option Plan, and Grant of Stock Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the results of the vote of its annual general and extraordinary shareholders' meeting (the “Meeting”) held on February 20, 2024, via video conference at 10:00 a.m. (EST).

Feb 20, 2024 08:45 am ET

Devonian Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued patent no. 11,723,938 B2 entitled, “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease” covering a method for treating inflammatory bowel disease (“IBD”) such as ulcerative colitis and Crohn’s

Jan 19, 2024 04:42 pm ET

Devonian Seeks Shareholders Approval for Share Consolidation

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that during its general annual and special meeting of shareholders (the “Meeting”), which will be held virtually on February 20, 2024, the Corporation will seek the authorization of the shareholders of the Corporation (the “Shareholders”) to allow the board of directors of the Corporation (the “Boa

Dec 04, 2023 08:45 am ET

Devonian Bolsters Leadership Team and Aligns Strategy to Accelerate Clinical Development and Drive Revenue Growth and Commercial Success

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that it has implemented changes to its management team (the ”Management”) and Board of Directors (the “Board”) in order to focus attention, maximize near and long-term revenue growth, and accelerate the clinical development program for ThykamineTM in atopic dermatitis.

Nov 08, 2023 08:45 am ET

Devonian Files Patent Cooperation Treaty (PCT) Application for Thykamine™ in Wound Healing

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that the Corporation has filed a Patent Cooperation Treaty (PCT) patent application for seeking protection for thylakoids developed by the company such as Thykamine™ in wound healing. The filing of this PCT application will give the Corporation the option of seeking patent protection in about 157 PCT contrac

Sep 01, 2023 04:00 pm ET

Devonian Announces Closing of a Private Placement of $500,000

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceeds of $499,999.94 (the “Offering”). The Offering consisted of the issuance of 2,272,727 units of the Corporation (the “Units”) at a price of $0.22 per Unit. Each Unit consists of one subordinate voting share of the Corporati

Jun 20, 2023 08:45 am ET

Devonian Health Group Receives a Notice of Allowance for Issuance of a U.S. Patent On a Method of Treatment of Inflammatory Bowel Disease.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, , is pleased to announce that the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for Devonian’s Patent application No.: 16/998.004 entitled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease”. This U.S. patent application is an addition to Devonian’s exis

Jun 06, 2023 06:30 pm ET

Devonian Announces Closing of a Private Placement of $1.2 Million

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of $1,199,664.75 (the “Offering”). The Offering consisted of the issuance of 7 997 765 units of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit consists of one subordina

May 19, 2023 04:00 pm ET

Devonian Announces Private Placement of up to $5 Million

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce its intention to complete a non-brokered private placement with investors relying on prospectus exemption pursuant to Regulation 45-106 respecting Prospectus Exemptions (the “Offering”) for a maximum of up to 33,333,333 units of the Corporation (the “Units”), at a price of $0.15 per Unit, for a

May 16, 2023 08:45 am ET

Devonian Health Group Announces Presentation of Thykamine™ Efficacy Results in Atopic Dermatitis at the World Congress of Dermatology and Provides Thykamine™ Clinical Development Program Update.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that results from phase 2 clinical study in mild-to-moderate atopic dermatitis (‘‘AD’’) will be presented at the upcoming 25th World Congress of Dermatology (‘‘WCD’’) to be held in Singapore from July 3rd to 8th. Results from the study will be made available on Devonian’s website following the poster p

May 12, 2023 08:45 am ET

Devonian Health Group Announces the Appointment of New Board Members and Grant of Stock Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today that Mr David Baker, Edouard Dahl and Jean Forcione were appointed as a new independent directors to the Company’s Board of Directors. The Corporation also announced the grant of options to directors and consultants.

May 11, 2023 08:55 am ET

Devonian Announces Filing of Preliminary Base Shelf Prospectus

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has filed and obtained a receipt for its preliminary short form base shelf prospectus (“Preliminary Shelf Prospectus”) with the securities regulatory authorities in each of the provinces of Canada (excluding the territories). Once a receipt for the final short form base shelf prospectus (“Shelf Pr

Mar 30, 2023 04:00 pm ET

Devonian Announces Approval of Amendments to its Stock Option Plan and its Restricted Share Unit Plan

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that at the annual and special meeting of its shareholders on March 17, 2023 (the “Meeting”), shareholders approved the renewal of the Corporation stock option plan (the “Option Plan”), as amended, and the renewal of the Corporation restricted share unit plan (the “RSU Plan”), as amended. Pursu

Mar 24, 2023 04:00 pm ET

Devonian Health Group Announces voting results of the Annual General and Special Meeting and welcome new board members

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the voting results of its Annual General and Special Meeting held on March 17, 2023 in person and via videoconferencing. The number of shares represented in person or by proxy represented 42.54% of vote on all issued and outstanding shares of Devonian Health Group, Inc.

Feb 22, 2023 08:45 am ET

Devonian Health Group Announces Hybrid Shareholders’ Annual General and Special Meeting

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that its Hybrid Annual General and Special Meeting of shareholders will take place on March 17, 2023, at 14:00 p.m. Eastern Time. The hybrid meeting will be held both in-person and virtually.

Jan 26, 2023 08:45 am ET

Devonian Health Group Announces its Participation at BIO CEO & Investor Conference

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that Mr. Pierre Montanaro, President and Chief Executive Officer of the Corporation, is scheduled to present at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis on February 6-9, 2023.

Jan 06, 2023 04:00 pm ET

Devonian Health Group Announces Executive Change and Grant of Stock Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian, its subsidiary Altius Healthcare inc. (‘‘Altius’’) and grant of options to directors and a consultant.

Oct 24, 2022 08:45 am ET

Devonian Health Group Inc. to Participate in Three Renmark’s Virtual Non-Deal Roadshow Series

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that they will be participating in three Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss the latest investor presentation.

Oct 12, 2022 08:45 am ET

Devonian to Present Thykamine™ Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today its presence at the upcoming 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases (‘‘ADDDS’’) held on November 1-3, 2022, in Boston, MA, USA.

Oct 06, 2022 08:45 am ET

Devonian Health Group Announces Peer-Reviewed Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD ; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced the publication of Thykamine™ positive phase 2 trial in adult patients with mild-to-moderate Atopic Dermatitis (AD) in the peer-reviewed Journal of Drugs in Dermatology (JDD).

Sep 07, 2022 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of the following units in settlement of interests owed to holders of debentures issued in the private placement, as announced by press releases dated August 31, 2018:

Aug 29, 2022 04:00 pm ET

Devonian Announces Executive Changes, Grant of Stock Options and Settlement of Interests and Repayment of Principal Amount Owed to a Debenture Holder

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today executive changes within Devonian and its subsidiary Altius Healthcare Inc. ("Altius").

May 26, 2022 08:45 am ET

Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD ; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced the acceptance for publication of results from its positive phase 2 trial of Thykamine™ in patients with mild-to-moderate Atopic Dermatitis (AD) in the peer-reviewed Journal of Drugs in Dermatology (JDD).

Mar 17, 2022 04:30 pm ET

Devonian Announces Adoption of Restricted Share Unit Plan

Mar 10, 2022 08:45 am ET

Devonian Health Group Announces Trading on the OTCQB® Market Under Symbol DVHGF

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has initiated quoting activity on the OTCQB® Venture Market (the “OTCQB”). Furthermore, Devonian has received the confirmation of its eligibility for settlement and transfer of its shares in the United States with The Depository Trust Company (“DTC”).

Mar 07, 2022 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to holders of debentures issued in the private placement, as announced by a press release dated August 31, 2018:

Mar 01, 2022 09:00 am ET

Devonian Health Group Announces Voting Results of the Annual General and Special Meeting and Welcomes New Board Members

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the voting results of its Annual General and Special Meeting held on February 25, 2022 via videoconferencing. The number of shares represented in person or by proxy represented 66.72 % of vote on all issued and outstanding shares of Devonian Health Group Inc.

Jan 31, 2022 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder and Grant of Stock Options

Devonian Health Group Inc. (“ Devonian” or the “ Corporation”) ( TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018:

Jan 27, 2022 09:00 am ET

Devonian Announces Adoption of Shareholder Rights Plan and Modification to a Private Placement

Jan 11, 2022 08:45 am ET

Devonian Health Group Announces Application for OTCQB Listing.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has applied for its subordinate voting shares (the "Shares") to be trading on the OTCQB® Venture Market (the “OTCQB”), a U.S. trading platform operated by the OTC Markets Group in New York. The quotation of the Company's common shares on the OTCQB remains subject to the approval of the OTC Markets Group and

Dec 08, 2021 08:45 am ET

Devonian Health Group Announces Publication of Article on Potential Use of Thykamine™ in the Treatment of Covid-19 in the International Journal of Noncommunicable Diseases

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the publication of an article in the peer-reviewed International Journal of Noncommunicable Diseases describing the potential use of Thykamine™ as a therapeutic agent for Covid-19.

Nov 30, 2021 09:00 am ET

Devonian Announces Closing of an Oversubscribed Private Placement of $10,000,000.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed the second tranche of a non-brokered private placement which was over-subscribed by issuing 25,806,997 units (the “Units”) at a price of $0.30 per Unit for aggregate gross proceeds of $7,742,099.10 (the “Offering”). Each Unit consists of one subordinate voting share and one share purchase warrant

Nov 24, 2021 04:00 pm ET

Devonian Announces the Issuance of Subordinate Voting Shares in Settlement of a Debt Owed to a Consultant and the Grant of Stock Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of 1,311,553 subordinate voting shares (the “Shares”) at a price of $0.352 per Share. The Shares will be issued in settlement of a debt owed to 9294-5039 Québec Inc. (“9294”), a consultant of the Corporation’s wholly-owned subsidiary, Altius Healthcare Inc. (“Altius”), which provided consulting services in c

Nov 12, 2021 04:00 pm ET

Devonian Health Group Announces Closing of the First Tranche of a Private Placement of $2,292,199.50

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed the first tranche of a non-brokered private placement (the “Offering”) by issuing 7,640,665 units (the “Units”) at a price of $0.30 per Unit for aggregate gross proceeds of $2,292,199.50. Each Unit consists of one subordinate voting share and one share purchase warrant (a “Warrant”). Each

Nov 04, 2021 08:45 am ET

Devonian Health Group Announces Its Participation at BIO-Partnering During JP Morgan Healthcare Conference 2022, Being Held Virtually on January 10 to 14, 2022.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce its participation at BIO-partnering during the JP Morgan Healthcare Conference 2022, being held virtually on January 10 to 14, 2022.

Sep 30, 2021 08:45 am ET

Devonian Health Group Announces Appointment of Martin Moreau as Vice-President Finance and as a New Member of its Board of Directors

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce the appointment of Martin Moreau as Vice-President Finance of the Corporation and to its board of directors, effective September 27, 2021.

Sep 13, 2021 08:51 am ET

Devonian Health Group Announces Closing of a Private Placement

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed a private placement (the “Offering”) by issuing 2,415,090 units (the “Units”) at a price of $0.44 per Unit for aggregate gross proceeds of $1,062,639.60. Each Unit consists of one subordinate voting share and one share purchase warrant ( a “Warrant”). Each Warrant will entitle its holder t

Sep 08, 2021 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

The issuance of Units is subject to the approval of the TSX Venture Exchange and will be subject to a hold period of 4 months and one day.

Aug 31, 2021 08:45 am ET

Devonian Health Group Announces Exclusive Distribution, Sales and Marketing Agreement for Purgenesis™ Anti-aging Products in Middle East Countries

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that they have entered into an exclusive distribution, sales and marketing agreement with Nexcure Pharma PVT Ltd (“Nexcure”), a leading pharmaceutical company with presence across India and the AfME region. The agreement grants Nexcure the exclusive right to distribute, market and sell Purgenesis™ cosmeceutical products in the M

Aug 26, 2021 08:45 am ET

Devonian Health Group Inc. Announces Its Participation at Virtual BioPlus-Interphex Korea 2021 to Take Place From August 31st to September 15, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products announced today that the Company’s President and Chief Executive Officer, Dr. Andre P. Boulet, will be participating in Virtual BioPlus-Interphex Korea scheduled on August 31st to September 15, 2021.

Jul 27, 2021 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder

Devonian Health Group Inc. (“ Devonian” or the “ Corporation”) ( TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018:

Jul 27, 2021 11:59 am ET

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-deal Roadshow Series in Chicago (USA) Today July 27, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series in Chicago (USA) to discuss its latest corporate presentation today, July 27 at 12:00 PM CST. Devonian Health Group Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Jul 20, 2021 02:30 pm ET

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-deal Roadshow Series in Los Angeles (USA) Today July 20, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series in Los Angeles (USA) to discuss its latest corporate presentation today, July 20 at 1:00 PM PST. Devonian Health Group Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live eve

Jun 14, 2021 12:05 pm ET

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series for Vancouver Today June 14, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series for Vancouver to discuss its latest investor presentation today, June 14 at 13:00pm PT. Devonian Health Group Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Jun 03, 2021 08:45 am ET

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series for Montreal and East of Canada Today June 3rd, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series for Montreal and east of Canada to discuss its latest investor presentation today, June 3rd at 10:00 AM EDT. Devonian Health Group Inc. welcomes stakeholders, investors, and other individual followers to register a

May 26, 2021 08:45 am ET

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series in Boston (USA) Today, May 26, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series in Boston (USA) to discuss its latest corporate presentation today, May 26 at 10:00 AM EDT. Devonian Health Group Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

May 13, 2021 09:00 am ET

Devonian Heath Group Inc. to Present at the Canada India Healthcare Summit 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products is pleased to announce that Dr. André Boulet, President and CEO, will present at the Canada India Healthcare Summit Conference being held virtually from May 20-21, 2021.

May 11, 2021 09:00 am ET

Devonian Heath Group Inc. to Participate in Renmark’s Virtual Non-deal Roadshow Series on Thursday, May 13, 2021

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, May 13 at 10:00 AM EDT. Devonian Health Group Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.

Apr 14, 2021 08:45 am ET

Devonian Health Group Inc. Retains Renmark Financial Communications Inc. to Provide Investor Relations Services

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.

Mar 30, 2021 08:45 am ET

Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine™ for the Treatment of Cardiovascular Diseases.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 16/347.613, titled "Composition for the Prevention and/or Treatment of Cardiovascular Diseases", covering the use of Thykamine™ as method for treating cardiovascular diseases.

Mar 25, 2021 08:45 am ET

Devonian Health Group Provides More Details on Previously Announced Positive Topline Results From Phase 2 Clinical Trial of Thykamine™ in Adult Population with Mild-to-Moderate Atopic Dermatitis and t

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, provides further details on previously announced results of Thykamine™ Phase 2 clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).

Mar 05, 2021 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the issuance of the following units in settlement of interests owed to holders of debenture issued in the private placement, as announced by press releases dated July 19, 2018 and August 31, 2018:

Feb 18, 2021 09:30 am ET

Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced that Thykamine™ met the primary endpoint in its Phase 2 Study for the treatment of mild-to-moderate atopic dermatitis (AD).

Jan 28, 2021 08:45 am ET

Devonian Health Group Announces Voting Results of The Annual General and Special Meeting

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the voting results of its Annual General and Special Meeting held on January 27, 2021 via videoconferencing. The number of shares represented in person or by proxy represented 74.32 % of vote on all issued and outstanding shares of Devonian Health Group Inc.

Jan 22, 2021 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder

Devonian Health Group Inc. (“ Devonian” or the “ Corporation”) ( TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018:

Dec 30, 2020 08:45 am ET

Devonian Health Group Announces Closing of a Private Placement and the Grant of Stock Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed a private placement (the “Offering”) by issuing 10,100,000 units (the “Units”) at a price of $0.12 per Unit for aggregate gross proceeds of $1,212,000. Each Unit consists of one subordinate voting share and one-half (1/2) of one share purchase warrant (each whole share purchase warrant, a “War

Oct 09, 2020 04:00 pm ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to Debenture Holders

Devonian Health Group Inc. (“ Devonian” or the “ Corporation”) ( TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to a holders of debenture issued in the private placement, as announced by press releases dated July 19, 2018:

Jul 30, 2020 04:30 pm ET

Devonian Announces Correction to Press Release Issued July 28, 2020

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today that a correction had to be made to the press release issued on July 28, 2020, concerning the granting of stock options:

Jul 28, 2020 08:45 am ET

Devonian Announces the Issuance of Units in Settlement of Interests Owed to a Debenture Holder and Stock Option Grants

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today the issuance of the following units in settlement of interests owed to a holder of debentures issued in the private placement, as announced by press releases dated July 19, 2018:

Jun 15, 2020 08:45 am ET

Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine™ for the Treatment of Ulcerative Colitis

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 15/772,155, titled, "Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease," covering the use of Thykamine™ for the treatment of Ulcerative Colitis.

Jun 10, 2020 08:45 am ET

Devonian Health Group Announces Completion of Enrollment in Its Phase 2 Clinical Trial of Thykamine™ for the Treatment of Mild-to-Moderate Atopic Dermatitis in Adult Population

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that it has completed the patient enrollment in its Phase 2 trial to evaluate the efficacy and safety of Thykamine™ for the treatment of mild-to-moderate atopic Dermatitis (“AD”) in adult patients. Top-line results for the trial are expected to be reported November 2020.

Jun 05, 2020 08:45 am ET

Devonian Health Group Announces Change to its Board of Directors

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that Mr. Guy Dancosse has been appointed to the Corporation’s Board of Directors, effective immediately. The Corporations also announces the departure of Mr. Borys Chabursky from its Board of Directors.

Jun 04, 2020 08:45 am ET

Devonian Health Group Announces an Exclusive Strategic Alliance with CannTx Life Sciences for the development of Cannabinoid-based Pharmaceutical Drugs.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical company, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announced a Strategic Alliance with CannTx Life Sciences Inc. (“CannTx”), a privately-owned cannabis producer licensed by Health Canada under the Cannabis Act.

May 21, 2020 08:45 am ET

Devonian Health Group Announces the nomination of Dr André P. Boulet to the American Botanical Drug Association.

May 04, 2020 08:45 am ET

Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces the closing of a non-brokered private placement (the “Offering”) for an aggregate gross proceeds of $1,805,000. The Offering was previously announced in the press releases issued on April 22 and April 24, 2020.

Apr 24, 2020 03:45 pm ET

Devonian Health Group Announces an Increase to Its Non-Brokered Financing to $2,000,000

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that it has taken the decision to increase the value of its $330,000 non-brokered private placement announced in press release dated April 22, 2020 for an aggregate gross proceeds of up to $2,000,000 (the “Offering”).

Apr 22, 2020 04:30 pm ET

Devonian Health Group Announces the Issuance of Securities in Interest Settlement Due to Debenture Holders, a $330,000 Non-Brokered Financing and the Grant of Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces that, conditional to the approval of the TSX Venture Exchange, it will issue the following securities in consideration of interest payable to the holders of debentures issued in the private placement as announced in press releases dated July 19, 2018 and August 31, 2018:

Feb 11, 2020 08:45 am ET

Devonian Health Group Announces R-Spinasome® Anti-aging Technology Global Sales and Marketing Partnership.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today it has signed an exclusive sales and marketing agreement with SkinSciPac Inc. (“SkinScipac”) to market worldwide cosmeceutical products derived from usage of its proprietary R-Spinasome® technology.

Jan 29, 2020 08:45 am ET

Devonian Issues Settlements of Interest Due to a Debenture Holder and Announces the Results of the Annual General Meeting of Shareholders

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, today announces the issuance of the following securities in consideration of interest it owes to a holder of debentures issued during the private placement as announced by press releases dated July 19, 2018:

Jan 23, 2020 08:45 am ET

Devonian Health Group Announces Presentation to the World Conference on Ageing and Gerontology and a Correction on Expiry Date of Warrants

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that Dr. André P. Boulet, president and CEO and Dr. Nathalie Boucher, Director Research of the Corporation, will present at the World Conference on Ageing and Gerontology, which is being held in Lisbon, Portugal from August 10-11, 2020. The presentation will detail in vitro mechanisms of action of R-Spinasome® as well as outcomes of the clini

Jan 15, 2020 08:45 am ET

Devonian Health Group Announces Cannabis Cutting-Edge Extraction Equipment in Its Montmagny Facility

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the signature of a lease Agreement with Hzb Pharma Canada Inc. (Hzb). This agreement includes the installation of state-of-the-art ethanol extraction equipment in Devonian’s facility in Montmagny (Quebec) for the purpose of extracting cannabinoids from hemp and cannabis plant. Both parties expect to collaborate in the development of cannabinoid-based botani

Oct 03, 2019 08:45 am ET

Devonian Health Group Obtains Cannabis Research License from Health Canada.

Sep 04, 2019 08:45 am ET

Devonian Health Group Announces the Formation of a Clinical Dermatology Advisory Board With Mandate to Assist in the Development of Cannabinoids-Based Pharmaceutical Products.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announced today that it has formed a Clinical Dermatology Advisory Board comprised of Canadian Key Opinion Leaders. The objective of the Clinical Dermatology Advisory Board is to provide clinical, scientific, research and strategic guidance to the Corporation as it continues to advance its pharmaceutical cannabis product development.

Aug 29, 2019 08:45 am ET

Devonian Health Group Announces the Publication of Positive Results of the Purgenesis® Anti-Aging Care Clinical Study in the Journal of Cosmetic Dermatology.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announced today the publication of positive results from the comparative clinical study on Purgenesis® Anti-aging Care in the management of lateral canthal lines (Crow’s feet).

Aug 21, 2019 09:51 pm ET

Devonian Announces the Closing of a $315,000 Private Placement and an Additional Loan of $500,000

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD) is pleased to announce the closing of a non-brokered private placement (the “Offering”) of 1,260,000 units of the Corporation (the “Units”), at a price of $0.25 per Unit, for...

Jul 23, 2019 08:45 am ET

Dr George G. Zhanel Joins Devonian’s Cannabinoids Scientific Advisory Board.

Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage biopharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announces that Professor George G. Zhanel has joined the Corporation’s Scientific Advisory Board for its Cannabinoids-based pharmaceutical program.

Jun 05, 2019 08:45 am ET

Devonian Announces the Filing of a New Patent Application Related to Use of Thylakoids as Delivery System for Cannabinoïds and Other Liposoluble Molecules

Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage biopharmaceutical corporation, today announced that the Corporation has filed a patent application for the use of thylakoids as delivery system for cannabinoids and other liposoluble molecules for pharmaceutical and cosmetic applications.

Jun 03, 2019 08:45 am ET

Devonian Signs a Binding Letter of Intent with Histapharm Inc. to Extract and Manufacture Their Proprietary Botanical Pharmaceutical Product and to Enter into a Strategic Partnership for the Developme

Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv:GSD), a clinical stage biopharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, and Histapharm Inc. ("Histapharm"), a company pioneering the control of histamine level in various dysfunctions, announced today that they have signed a binding Letter of Intent ("LOI") to negotiate the terms establishing Devonian as the exclusive site for the extraction and manufacturin

Apr 10, 2019 08:45 am ET

Devonian Health Group Announces the Formation of a Scientific Advisory Board with Mandate to Assist in the Development of Cannabinoïds-Based Pharmaceutical Products.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announced today that it has formed a Scientific Advisory Board comprised of experts in botany, chemistry, immunology, infectious diseases, drug discovery and development. This Scientific Advisory Board will assist Devonian’s Research and Development team in the development of cannabinoïds-based pharmaceutic

Apr 08, 2019 08:45 am ET

Devonian Health Group Announces the Publication of Results of in Vitro Assessment of the Antioxidant and UV Protection Properties of Thylakoid Extracts in Journal of Cosmetic Dermatology.

Apr 02, 2019 08:45 am ET

Devonian Healthcare Group Reports Key Financial Results for Quarter Ended January 31, 2019

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today reported key results from operations for the quarter ended January 31, 2019.

Mar 29, 2019 02:00 pm ET

Devonian Health Group Issues Securities in Interest Settlement Due to Debenture Holders and Grants Options

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage biopharmaceutical corporation, today announces the issuance of the following securities in consideration of interest payable to the Debenture holders issued in the private placement as announced in press releases dated July 19, 2018 and September 4, 2018:

Jan 31, 2019 01:30 pm ET

Devonian Announces Voting Results of the Annual General and Special Meeting

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation, today announces the voting results of its Annual General and Special Meeting held on January 29, 2019 in Quebec City, Quebec. The number of shares represented in person or by proxy represented 74.01 % of the total issued and outstanding Devonian’s shares.

Jan 29, 2019 08:45 am ET

Devonian Health Group Provides an Update on its Phase 2 Clinical Study in Atopic Dermatitis and Announces Plans for the First Photoprotection Product Issued From its Cosmeceutical R&D Program.

Jan 23, 2019 08:45 am ET

Devonian Health Group Announces the Refinancing of the Loan on Its Pharmaceutical Facility

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announced that it has refinanced the existing loan on its pharmaceutical facility. The loan from Investment Quebec (IQ) was terminated and replaced by one with a Private Group of Lenders (“PGL”). As of January 17, 2019, the residual on the IQ loan was $2,824,883. PGL has agreed to a loan of $3,

Dec 19, 2018 10:09 pm ET

Devonian Health Group Announces 2018 Annual General Shareholder’s Meeting

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV:GSD), a clinical stage biopharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announced that its Annual General Shareholders’ Meeting will be held on Tuesday, January 29, 2019 at 15:30 p.m. EST at Château Bonne Entente, 3400 Chemin Sainte-Foy, City of Québec, Québec.

Nov 12, 2018 10:03 am ET

Devonian Health Group Announces the Recognition of Sybil Dahan, President of Altius Healthcare, as Inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announces the recognition of Sybil Dahan, President of Altius Healthcare - commercial division of Devonian - as an inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.

Oct 03, 2018 08:45 am ET

Devonian Health Group Receives 2018 Best Anti-Aging Skin Treatment Technology from LUX Life Magazine.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announced that its Purgenesis™ anti-aging treatment was awarded the 2018 Best Anti-Aging Skin Treatment Technology from United Kingdom-based LUX Life Magazine (LUX).

Aug 06, 2018 04:00 pm ET

Devonian Health Group provides an update on its previously announced private placement

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSX VENTURE:GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, is pleased to...

Jul 31, 2018 08:45 am ET

Devonian Health Group Announces issuance of European Patent for its Purgenesis™ anti-aging treatment

Jul 19, 2018 08:45 am ET

Devonian Health Group announces Non-Brokered Financing by way of a private placement of Convertible Debenture

Jul 18, 2018 08:45 am ET

Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018

Jun 29, 2018 08:45 am ET

Devonian Announces Grant of Options

Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) announces that the Board of Directors has approved the grant of options (the ‘‘Options’’) to purchase subordinate voting shares in the capital of the Corporation. Such...

Jun 28, 2018 08:45 am ET

Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy

Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) and Folia Biotech inc. (‘‘Folia’’) today announce the signing of a non-binding Letter of Intent (‘‘LOI’’) to exclusively negotiate the terms establishing an...

Jun 27, 2018 08:45 am ET

Devonian Health Group Announces issuance of United States Patent for its Purgenesis™ anti-aging treatment

Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXv:GSD) today announced that the United State Intellectual Property Office issued a Notice of Allowance for United States Patent application # 13/261,472, entitled “The use of a...

Jun 26, 2018 08:45 am ET

Devonian Health Group announces the commercial launch of the Purgenesis(TM) Anti-aging treatment at the Canadian Dermatology Association’s annual conference

May 16, 2018 08:45 am ET

Devonian Health Group Announces Canadian Patent for its Purgenesis™ anti-aging treatment

Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) today announced that the Canadian Intellectual Property Office issued a Notice of Allowance for Canadian Patent application # 2,699,676, entitled “The use of a...

Mar 21, 2018 09:00 am ET

Devonian Announces Grant of Options

QUEBEC CITY, March 21, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) announces that the Board of Directors has approved the grant of options (the ‘‘Options’’) to purchase subordinate voting shares in...

Feb 26, 2018 04:09 pm ET

IIROC Trade Resumption - Devonian Health Group Inc.

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2018) - Trading resumes in:

Feb 26, 2018 03:13 pm ET

IIROC Trading Resumption - GSD

VANCOUVER, Feb. 26, 2018 /CNW/ - Trading resumes in:

Feb 23, 2018 04:42 pm ET

CORRECTION -- Devonian Health Group Inc.

The corrected release follows:

Feb 01, 2018 08:30 am ET

Devonian Announces Acquisition of Altius Healthcare

Transaction highlights:

Jan 31, 2018 11:36 am ET

IIROC Trade Halt - Devonian Health Group Inc.

Vancouver, British Columbia--(Newsfile Corp. - January 31, 2018) - The following issues have been halted by IIROC:

Jan 31, 2018 10:37 am ET

IIROC Trading Halt - GSD

VANCOUVER, Jan. 31, 2018 /CNW/ - The following issues have been halted by IIROC:

Jan 12, 2018 10:12 am ET

Devonian Announces voting results of the Annual General and Special Meeting

QUEBEC CITY, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSX VENTURE:GSD), a clinical stage botanical pharmaceutical corporation, today announces the voting results of its Annual General and Special Meeting held on...

Nov 16, 2017 08:45 pm ET

Devonian Announces the Filing of New Patent Application for Thykamine™

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Nov 09, 2017 08:45 am ET

Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine™ in Adult patients with Mild-to-Moderate Atopic Dermatitis

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Sep 28, 2017 11:30 am ET

InvestmentPitch Media Invites Investors to the GCFF Conference in Toronto on September 30, 2017 - Video Hosted on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - September 28, 2017) - InvestmentPitch Media would like to invite investors to the 18th annual GCFF conference on Saturday September 30th, 2017 at the Courtyard & Towneplace Suites, in Markham, Ontario, located at 7095 Woodbine Avenue, from 8:45 AM to 5:15 PM.

Sep 28, 2017 08:45 am ET

Devonian Health Announces Purgenesis™ anti-aging treatment marketing and distribution partnership

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES...

Jul 12, 2017 11:16 am ET

Devonian Health Group Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) a clinical stage botanical pharmaceutical corporation, is...

Jul 07, 2017 09:33 am ET

Devonian Announces Grant of Options

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) announces that the Board of Directors has approved the grant of options...

Jun 22, 2017 08:58 am ET

Devonian Announces Plans for its Dermatology program of Thykamine(TM)

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Devonian Health Group Inc. (TSX VENTURE:GSD) ("Devonian" or the "Corporation") (TSXV: GSD) today announces key study design details for its planned...

Jun 21, 2017 11:00 am ET

Devonian Announces Issuance of One New Key Patent and the Granting of a Trademark

May 31, 2017 09:43 am ET

Devonian Announces the Appointment of Two New Members to the Board of Directors and Senior Management Changes to Support Growth Strategy

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE:GSD) today announced the nomination of Mr. Jacques Bernier, BPharm., MBA and...

May 18, 2017 07:04 pm ET

Devonian Announces the Listing of its Shares on the TSX Venture Exchange

May 18, 2017 07:04 pm ET

Devonian Announces the Listing of its Shares on the TSX Venture Exchange

Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSX VENTURE: GSD) is pleased to announce the receipt of the final bulletin from the TSX Venture Exchange in connection with the completion of the previously announced qualifying transaction and the concurrent public offering. Consequently, the subordinate voting shares of the Corporation will began trading on the TSX Venture Exchange at the opening of markets on May 19, 2017 under the symbol "GSD" and the common shares of Orletto will be delisted.

May 18, 2017 05:16 pm ET

IIROC Trading Resumption - BCP; GSD; ETMC.H

VANCOUVER, May 18, 2017 /CNW/ - Trading resumes in:

Ad blocking detected

Devonian Health Group Inc. (V:GSD)

Business Focus: Pharmaceuticals (NEC)